Multicenter, Randomized, Double-blind, Placebo-controlled Two Stage Study to Characterize the Efficacy, Safety, Tolerability and Pharmacokinetics of GZ/SAR402671 in Patients at risk of Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD) - SAVE-PKD

GENZYME CORPORATIO0 个研究点目标入组 982 人开始时间: 2021年6月17日最近更新: 2021年8月24日

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方
入组人数: 982

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•- Male or female adult with ADPKD with age at the time the consent is signed:
•a) between 18 to 50 years (both inclusive) for patients from Stage 1
•b) between 18 to 50 years (both inclusive) for patients from Stage 2 with eGFR between 45 and 89.9 mL/min/1.73 m2 during screening period*
•c) between 18 to 55 years (both inclusive) for patients from Stage 2 with eGFR between 30 and 44.9 mL/min/1.73 m2 during screening period*
•Diagnosis of ADPKD in patients with a family history, will be based on unified Pei criteria.
•In the absence of a family history, the diagnosis will be based on the presence of renal cysts bilaterally, totaling at least 20, in the absence of findings suggestive of other cystic renal diseases.
•- Mayo Imaging Classification of ADPKD Class 1C, 1D or 1E**.
•** TKV volume must be confirmed by a central reader prior to Visit 3
•- Estimated glomerular filtration rate between 45 to 89.9 mL/min/1.73 m2 during screening period* (Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] for Stage 1.
•Estimated glomerular filtration rate between 30 to 89.9 mL/min/1.73 m2 during screening period* (Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]) for Stage 2.
•*Eligibility will be confirmed by eGFR value from one of the two first prerandomization eGFR measurements.
•- Stable treatment regimen of antihypertensive therapy for at least 30 days prior to the screening visit for hypertensive patient.
•- Able to read, comprehend and respond to the study questionnaires.
•- Patient has given voluntary written informed consent before performance of any study related procedures not part of standard medical care.
•- Patient does not have access to tolvaptan at the time of study start or tolvaptan is not indicated for treatment of patient according to treating physician (patient does not meet recommended criteria for treatment, refuses to initiate or does not tolerate treatment with tolvaptan).
•-The patient, if female of childbearing potential, must have a negative blood pregnancy test [beta human chorionic gonadotropin (ß-hCG)] at the screening visit and a negative urine pregnancy test at the baseline
•- Female patients of childbearing potential and male patients must agree to practice true abstinence in line with their preferred and usual lifestyle or to use double-contraceptive methods (including a highly effective method of contraception for female participants of childbearing potential) for the entire duration of the study and for at least 6 weeks for females and 90 days for males following their last dose of study drug.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 982
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

排除标准

•-Systolic blood pressure >160 mm Hg at Run-in and Baseline visits
•-Administration within 3 months prior to the screening visit of tolvaptan or other Polycystic Kidney Disease-modifying agents (somatostatin analogues).
•-Current participation in another investigational interventional study or use of investigational medicinal product (IMP), within 3 months or 5 half lives, whichever is longer, before randomization.
•- The patient has a positive result of any of the following tests: hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (anti HCV) antibodies, anti-human immunodeficiency virus 1 and 2 antibodies (anti HIV1 and anti HIV2 Ab). Patients with a positive hepatitis B surface antibody (HBsAb) test are eligible if other criteria are met (ie, negative tests for: HBsAg, hepatitis B core antibody [HBcAb]). Patients immune due to natural infection (positive hepatitis B surface antibody (HBsAb), negative hepatitis B surface antigen (HBsAg) and positive hepatitis B core antibody [HBcAb]) are eligible if they have negative HBV DNA test.
•- A history of drug and/or alcohol abuse within the past year prior to the screening visit. A history of alcohol dependence within the 5 years prior to the screening visit.
•-The patient is scheduled for in-patient hospitalization including elective surgery, during the study.
•-The patient has a clinically significant, uncontrolled medical condition that, in the opinion of the investigator, would put the safety of the subject at risk through participation, or which would affect the efficacy or safety analysis if the condition exacerbated during the study, or that may significantly interfere with study compliance, including all prescribed evaluations and follow-up activities.
•-The patient, in the opinion of the investigator, is unable to adhere to the requirements of the study or unable to undergo study assessments (eg, has contraindications to pupillary dilation or unable to undergo magnetic resonance imaging (MRI ) [For example: patient’s weight exceeds weight capacity of the MRI, ferromagnetic metal prostheses, aneurysm clips, severe claustrophobia, large abdominal/back tattoos, etc]).
•-Any country-related specific regulation that would prevent the patient from entering the study.
•-The patients did not adhere to treatment (<70% compliance rate) in the run-in
•-The patient has, according to World Health Organization (WHO) Grading, a cortical cataract >onequarter of the lens circumference (Grade cortical cataract-2 [COR-2]) or a posterior subcapsular cataract >2 mm (Grade posterior subcapsular cataract-2 [PSC-2]). Patients with nuclear cataracts will not be excluded.
•-The patient is currently receiving potentially cataractogenic medications, including a chronic regimen (more frequently than every 2 weeks) of any route of corticosteroids (including medium and high potency topical steroids) or any medication that may cause cataract, according to the Prescribing Information
•-The patient has received strong or moderate inducers or inhibitors of CYP3A4 within 14 days or 5 half-lives, whichever is longer, prior to randomization. This also includes the consumption of grapefruit, grapefruit juice, or grapefruit containing products within 72 hours of starting GZ/SAR402671 administration
•-The patient is pregnant, or lactating
•-Liver enzymes (alanine aminotransferase [ALT]/aspartate aminotransferase [AST]) or total bilirubin >2 times the upper limit of normal unless the patient has the diagnosis of Gilbert syndrome

研究者

发起方

GENZYME CORPORATIO

相似试验

进行中（未招募）

不适用

Multicenter, Randomized, Double-blind, Placebo-controlledStudy to Evaluate the Safety and Tolerability of OralLixivaptan Capsules in Subjects with EuvolemicHyponatremiaEuvolemic hyponatremiaMedDRA version: 9.1Level: LLTClassification code 10021038Term: Hyponatremia

EUCTR2008-003191-21-CZCardiokine Biopharma, LLC200

进行中（未招募）

1 期

A Medical Research Study Designed to Determine if Venglustat can be a Future Treatment for ADPKD PatientsCongenital, hereditary and neonatal diseasesMedDRA version: 20.0Level: LLTClassification code 10036046Term: Polycystic kidney, autosomal dominantSystem Organ Class: 100000004850

EUCTR2017-004084-12-CZGenzyme Corporation982

进行中（未招募）

1 期

EUCTR2017-004084-12-NLGenzyme Corporation982

进行中（未招募）

1 期

Study to test IMU-838 in patients with progressive multiple sclerosisProgressive forms of Multiple SclerosisMedDRA version: 26.1Level: PTClassification code 10053395Term: Progressive multiple sclerosisSystem Organ Class: 10029205 - Nervous system disorders

EUCTR2021-000048-23-NLImmunic AG450

招募中

2 期

Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with Progressive Multiple Sclerosis

2024-514617-35-00Immunic AG230